INmune Bio Current Cash

INmune Bio (INMB) currently reports a current cash of $21M as of March 2026. That compares with $19M in the prior-year period — up 10.5% year over year. Use the charts on this page to explore INmune Bio's current cash history and peer comparisons.

INmune Bio's current cash increased from $19M to $21M — a 10.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

INmune Bio reported $21M in current cash as of March 2026. That compares with $19M in the prior-year period — up 10.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $21M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for INmune Bio, and consider following INMB for alerts when major investors trade the stock.

INmune Bio is classified in the Healthcare sector. On current cash, it currently shows $21M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INMB with unrelated industries.